✨ Vonoprazan Fumarate (CAS 881681-01-2) | Pharmaceutical-Grade Potassium-Competitive Acid Blocker (P-CAB) ✨
🧪 Product Overview
Vonoprazan Fumarate (CAS 881681-01-2) is a potassium-competitive acid blocker (P-CAB) with the molecular formula C₂₁H₂₀FN₃O₆S and molecular weight 461.46. This white to off-white crystalline powder (purity ≥98%) is clinically validated for treating acid-related gastrointestinal disorders, including erosive esophagitis, gastric ulcers, and duodenal ulcers. It inhibits H+/K+-ATPase with rapid onset and prolonged efficacy, outperforming traditional proton pump inhibitors (PPIs).
Key Functions:
Promotes healing of erosive esophagitis and peptic ulcers.
Enhances Helicobacter pylori eradication in combination therapy.
Serves as a pharmaceutical intermediate or reference standard for drug development.
Target Industries: Pharmaceutical manufacturing, biotechnology, and clinical research.
⭐ Key Advantages
| 🔹 Ultra-High Purity | 🔹 Rapid Action | 🔹 Dual Therapeutic Role |
|---|
| ≥98% HPLC-certified | Acid suppression within 30 minutes | Combines ulcer healing and H. pylori eradication |
| Batch-specific COA | 24-month shelf life under ambient storage | Reduces ulcer recurrence rates |
🏭 Applications
Erosive Esophagitis: Oral formulations for mucosal repair.
Peptic Ulcer Therapy: Effective for gastric and duodenal ulcers.
H. pylori Eradication: Used with antibiotics for dual-action protocols.
Pharmaceutical Synthesis: Intermediate for advanced P-CAB formulations.
📊 Quality Assurance
Testing Standards: Complies with USP/EP pharmacopeial guidelines.
Analytical Methods: Validated via HPLC, NMR, and mass spectrometry.
Packaging: Customizable batches (1kg–25kg) with moisture-proof sealing.
📈 Market Insights
The global peptic ulcer therapeutics market is projected to grow at 5.8% CAGR (2025–2030), driven by demand for non-PPI therapies. Asia-Pacific leads API production, with China dominating cost-efficient manufacturing.
China
